Neurocrine Biosciences, Inc. (NBIX) — Stock Score Summary

Neurocrine Biosciences, Inc. (NBIX) has a MoatMap StockRank of 97/100 based on Quality (79/100), Value (36/100), and Momentum (76/100) factor scores. The current signal is STRONG BUY. While Neurocrine is a high-quality biopharmaceutical company with a strong franchise in Ingrezza, it does not align with our active 18-month macro themes. We prefer to allocate capital where both quality and powerful macro tailwinds intersect.

Neurocrine Biosciences is a neuroscience-focused pharmaceutical company discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company possesses a deep pipeline and commercialized products addressing specific, often underserved, neurological conditions, leveraging proprietary research and development capabilities. Neurocrine is a specialized biopharmaceutical company known for its expertise in neuroscience, focusing on developing first-in-class or best-in-class treatments for central nervous system disorders.

Key Financial Metrics

Price$154.84
Market Cap$15.7B
P/E (TTM)23.96
P/E (Forward)12.26
Price/Book4.60
Return on Equity22.5%
Return on Invested Capital16.4%
Debt/Equity13.60
Gross Margin64.4%
Operating Margin22.8%
Revenue Growth42.2%
Free Cash Flow$591M

Neurocrine Biosciences, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Neurocrine Biosciences, Inc.’s (NBIX) StockRank?
MoatMap’s StockRank for Neurocrine Biosciences, Inc. (NBIX) is 97/100, with a Strong Buy signal. It is a composite of Quality (79), Value (36), and Momentum (76) factor ranks across MoatMap’s 19,000+ stock universe.
Does Neurocrine Biosciences, Inc. have an economic moat?
Neurocrine Biosciences, Inc. (NBIX) has a Quality factor score of 79/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Neurocrine Biosciences, Inc. a buy, hold, or sell?
MoatMap’s current signal for Neurocrine Biosciences, Inc. (NBIX) is Strong Buy, based on a StockRank of 97/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Neurocrine Biosciences, Inc. in?
Neurocrine Biosciences, Inc. (NBIX) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).
Browse all ranked stocksNBIX deep dive reportAI ChampionsHow we score stocksSense-check another stock